Trials / Active Not Recruiting
Active Not RecruitingNCT05886634
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
A Phase II Study of Adenosine Receptor (A2A and A2B) Inhibition (AB928) in Combination With Anti-PD-1 Therapy (AB122) in Patients With Advanced Dedifferentiated Liposarcoma
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Participants will have a diagnosis of dedifferentiated liposarcoma (DDLS) that has spread beyond its original location (advanced). In addition, their DDLS either has come back after treatment (recurrent), has spread to different parts of your body (metastatic), or is unable to be removed surgically (unresectable). The purpose of this study is to find out whether the combination of etrumadenant and zimberelimab is an effective treatment for people with advanced DDLS.
Conditions
- Dedifferentiated Liposarcoma
- Soft Tissue Sarcoma
- Sarcoma,Soft Tissue
- Sarcoma
- Recurrent Dedifferentiated Liposarcoma
- Unresectable Dedifferentiated Liposarcoma
- Metastatic Dedifferentiated Liposarcoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Etrumadenant | Will be administered PO daily for 24 weeks |
| DRUG | Zimberelimab | Will be administered IV every 2 weeks for 24 weeks |
Timeline
- Start date
- 2023-05-23
- Primary completion
- 2027-05-23
- Completion
- 2027-05-23
- First posted
- 2023-06-02
- Last updated
- 2025-10-20
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05886634. Inclusion in this directory is not an endorsement.